Secukinumab for moderate to severe plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 21 years old.
- You have plaque psoriasis that is moderate to severe, meaning it covers at least 10% of your body and affects quality of life.
- You have never had oral or injected medications for psoriasis (like methotrexate) or light therapy before.
- You are willing to have skin assessments and possibly stop the study drug during the trial.
- You do not have other uncontrolled health conditions or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.
This study looks at how well secukinumab works for psoriasis patients who also have a type of fatty liver disease called MASLD. It may help doctors understand if this treatment is a good option for people with both conditions.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests an oral medication (HSK47388) as a treatment for moderate-to-severe plaque psoriasis, the most common type. It may help reduce symptoms like red, scaly patches and improve quality of life.
This study tests whether adding metformin (a diabetes medicine) to secukinumab (a biologic injection) works better for people with moderate-to-severe plaque psoriasis who are overweight or obese. It might help control psoriasis and reduce inflammation.
This study tests an investigational drug called SHR-1139 for people with moderate-to-severe plaque psoriasis who have not responded well to previous biologic treatments. The goal is to see if it can reduce psoriasis symptoms safely.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.